Hepatitis C Global Market Report 2024

The hepatitis c market size has grown rapidly in recent years. It will grow from $59.58 billion in 2023 to $68.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth observed in the historical period can be attributed to factors such as blood transfusion practices, injection drug use, limited treatment options, and the development of direct-acting antivirals (DAAs).

The hepatitis c market size is expected to see rapid growth in the next few years. It will grow to $117.94 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The anticipated growth in the forecast period can be attributed to global elimination efforts, improved testing and screening practices, increasing healthcare spending, the integration of telemedicine, and the emergence of therapeutic combinations. Notable trends expected in the forecast period include a focus on accessible and affordable treatment options, targeted efforts for high-risk groups, advancements in drug formulations, collaborative initiatives and partnerships, as well as the integration of telehealth and digital solutions in hepatitis C management.

The hepatitis C market is anticipated to experience growth driven by an increase in viral infections. Viral infections, caused by viruses within the body, are addressed by hepatitis C treatment, which aims to eradicate the viral infection and restore the immune response in patients. As reported by the European Centre for Disease Prevention and Control, 14,560 cases of hepatitis C were reported in 29 European Economic Area (EEA) member states in 2021, marking an increase from the previous year's 13,914 cases. This rise in viral infections serves as a significant factor propelling the hepatitis C market.

The prevalence of hepatitis is expected to contribute to the growth of the hepatitis C market. Hepatitis, an inflammatory liver condition commonly caused by viral infections, particularly hepatitis viruses A, B, C, D, and E, is a focus area for the Hepatitis C market. Data from the World Health Organization (WHO) in July 2021 revealed an estimated 58 million individuals with chronic hepatitis C virus infection, experiencing 1.5 million new infections annually. The increasing prevalence of hepatitis is a key driver for the growth of the hepatitis C market.

A noteworthy trend gaining popularity in the hepatitis C market is the advancement in diagnostic technologies. Major companies in the market are adopting new technologies to maintain their market positions. In July 2022, F. Hoffmann-La Roche Ltd. introduced the Elecsys HCV Duo immunoassay, allowing the independent and simultaneous determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. The test aids in identifying patients recovering from or exhibiting symptoms of chronic infection, potentially leading to other diseases such as liver cancer.

Strategic alliances are a focal point for major companies operating in the hepatitis C market to strengthen their positions. In July 2021, Médecins Sans Frontières (MSF), FIND, and Treatment Action Group joined forces to address disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs). The partnership emphasizes the significance of collaborative efforts to save lives, reduce costs in national budgets, and prove cost-effective.

In September 2022, Gilead Sciences Inc. partnered with Brigham and Women's Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center for Health Advancement in Vietnam (HAIVN). This public-private initiative aims to improve the management of viral hepatitis in Vietnam and the Philippines, aligning with the global goal of hepatitis C elimination by 2030. The collaboration involves institutions such as Brigham and Women's Hospital and Beth Israel Deaconess Medical Center in the U.S. and Harvard Medical School.

Major companies operating in the hepatitis c market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffman La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sumitomo Corporation , GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Amgen Inc., Toray Industries Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., LEO Pharma A/S, Biocon Limited, Kadmon Holdings Inc.

North America was the largest region in the hepatitis C market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis c market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of hepatitis C are chronic hepatitis C, acute hepatitis C, and others. Chronic hepatitis C denotes a persistent infection caused by the hepatitis C virus, occurring when the body is unable to effectively combat the virus. Treatment options for chronic hepatitis C include antiviral drugs, vaccines, immune modulator drugs, surgery, and others. The diagnostic process typically involves liver biopsy, blood tests, imaging tests, and others, with distribution through hospital and retail pharmacies, as well as online pharmacies. End-users encompass hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, research institutes, and home care settings.

The hepatitis C market research report is one of a series of new reports that provides hepatitis C market statistics, including hepatitis C industry global market size, regional shares, competitors with a hepatitis C market share, detailed hepatitis C market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis C industry. This hepatitis C market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis C market consists of revenues earned by entities by providing shunt procedures, hepatic resection, and biopsies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C market also includes sales of ledipasvir and sofosbuvir, non-structural protein 5B (NS5B) polymerase inhibitors, non-structural protein 5A (NS5A) replication complex inhibitors, and elbasvir and grazoprevir drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.